secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001438533-23-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere reports Q2 loss, FILSPARI launch progress, and $445M bile acid portfolio sale
--------------------------------------------------------------------------------

- Net loss $85.6M ($1.13/share) vs $67M loss in prior year; revenue $59.7M from product sales $57M and licensing.
- FILSPARI launch: 417 new patient start forms in Q2; net sales $3.5M in Q2, $6.5M since Feb approval.
- Positive pegtibatinase Cohort 6 results: 67.1% mean tHcy reduction; Phase 3 study expected by year-end.
- Agreement to sell bile acid portfolio (Cholbam, Chenodal) to Mirum for up to $445M ($210M upfront); close Q3 2023.
- Cash $491.3M; topline confirmatory PROTECT data for IgAN sNDA expected late Q3/early Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000036/0001438533-23-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000036/tvtx-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001438533-23-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer